BCL2 and cancer: For example, though Bcl-2 can be a ruler of anti-apoptosis and thus cancer cell survival, cross-talk interactions between small GTPases which are pharmacologically inhibited actually reverted death phenotypes of Bcl-2 expressing cells, essentially modifying anti-apoptosis and thus providing an additional target for drug resistant cancers [78].